Revised Audited Financial Result for the Quarter and Year ended 31st March, 2025

Emphasis of matterProfit growth above 25%Revenue growth above 20%Results restatedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

—Next day

₹41.55

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%—

Pharmaceuticals peers, median of 148sector-0.0%—

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—-0.1—+0.1—

Next day

—+0.2—-0.0—

—+0.6—+0.8—

—+0.9—+0.3—

+0.0+1.0-1.0+0.0+0.0

—+0.7—-0.7—

—+1.8—+0.0—

15d

—+1.7—-0.8—

—+3.1—-0.7—

-9.6+1.7-11.3+0.6-10.2

—-1.0—-3.0—

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma Ltd (BSE: 524516) filed revised audited results for FY25. Revenue from operations stood at zero across all reporting periods, with total income of Rs. 66.14 lacs in FY25 vs Rs. 13.05 lacs in FY24, coming entirely from 'other income'. The company swung to a profit after tax of Rs. 40.41 lacs from a loss of Rs. 5.91 lacs in FY24, with basic EPS of Rs. 0.64 vs Rs. (0.10). A private placement of 74.43 lakh equity shares lifted share capital from Rs. 589 lacs to Rs. 1,397.02 lacs and boosted investments to Rs. 2,135.66 lacs and cash equivalents to Rs. 285.73 lacs. Total assets expanded sharply from Rs. 132.61 lacs to Rs. 2,560.02 lacs. The statutory auditor issued an unmodified opinion but flagged an Emphasis of Matter on unconfirmed loans and advances of Rs. 128.26 lacs whose recoverability could not be verified.

Likely market impact

The profit turnaround is driven mainly by investment/income returns on freshly raised capital rather than any core business activity, as operational revenue remains nil. The auditor's emphasis on unrecoverable loans is a red flag for shareholders, even though the balance sheet has been strengthened by the preferential allotment.